International journal of dermatology · 2026
Clinicopathologic and Immunohistochemical Features of Enfortumab Vedotin-Induced Cutaneous Toxicity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Repetto Federico, Jobbagy Soma, Lee Eudora, Russell-Goldman Eleanor E, Hoang Mai P, Chan May P, Semenov Yevgeniy, Nazarian Rosalynn M
Аннотация
BACKGROUND: Enfortumab vedotin (EV) frequently causes cutaneous eruptions that can mimic erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), complicating management decisions.
OBJECTIVE: The aim of this study was to define reproducible clinicopathologic patterns and evaluate immunohistochemical markers that distinguish EV-induced cutaneous toxicity (EVICT) eruptions from histologic mimics.
METHODS: This retrospective case series included nineteen patients receiving EV (twenty-four biopsies), compared with ten controls (erythema multiforme or SJS/TEN). Blinded review assessed histologic patterns and immunohistochemistry for immunoglobulin G (IgG), Nectin-4, and cytotoxic T-cells.
RESULTS: All cases showed interface dermatitis fitting one of four patterns: classic vacuolar, cytotoxic with epidermal dysmaturation, necrolytic SJS/TEN-like, or spongiotic interface. Epidermal "ring" mitoses were frequent in EV-related biopsies and absent in controls. Intercellular IgG staining occurred in 83% of EV cases versus 20% of controls, yielding an area under the curve of 0.86; any intercellular staining provided 82% sensitivity and 80% specificity, while moderate or strong staining achieved 100% specificity. Cytotoxic T-cell density and Nectin-4 expression did not reliably discriminate groups.
LIMITATIONS: Retrospective design, modest sample size, and potential confounding by concomitant therapies.
CONCLUSION: Intercellular IgG on routine immunohistochemistry, together with characteristic "ring" mitoses, provides a practical framework to identify enfortumab vedotin-associated eruptions and differentiate them from erythema multiforme and SJS/TEN.
OBJECTIVE: The aim of this study was to define reproducible clinicopathologic patterns and evaluate immunohistochemical markers that distinguish EV-induced cutaneous toxicity (EVICT) eruptions from histologic mimics.
METHODS: This retrospective case series included nineteen patients receiving EV (twenty-four biopsies), compared with ten controls (erythema multiforme or SJS/TEN). Blinded review assessed histologic patterns and immunohistochemistry for immunoglobulin G (IgG), Nectin-4, and cytotoxic T-cells.
RESULTS: All cases showed interface dermatitis fitting one of four patterns: classic vacuolar, cytotoxic with epidermal dysmaturation, necrolytic SJS/TEN-like, or spongiotic interface. Epidermal "ring" mitoses were frequent in EV-related biopsies and absent in controls. Intercellular IgG staining occurred in 83% of EV cases versus 20% of controls, yielding an area under the curve of 0.86; any intercellular staining provided 82% sensitivity and 80% specificity, while moderate or strong staining achieved 100% specificity. Cytotoxic T-cell density and Nectin-4 expression did not reliably discriminate groups.
LIMITATIONS: Retrospective design, modest sample size, and potential confounding by concomitant therapies.
CONCLUSION: Intercellular IgG on routine immunohistochemistry, together with characteristic "ring" mitoses, provides a practical framework to identify enfortumab vedotin-associated eruptions and differentiate them from erythema multiforme and SJS/TEN.